Clinical trial
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor…
NCT00290485 · Maisonneuve-Rosemont Hospital, Other · Unknown status
Key facts
| NCT number | NCT00290485 |
|---|---|
| Title | Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST) |
| Official title | A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor |
| Lead sponsor | Maisonneuve-Rosemont Hospital, Other |
| Collaborators | Hippocrate Research & Development |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumors |
| Intervention type | Drug |
| Interventions | Imatinib mesylate |
| Enrollment | 50 |
| Start date | Aug 1, 2005 |
| First posted | Feb 13, 2006 |
| Last update posted | Apr 7, 2006 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: